Victoria Werth, MD, discusses the FDA approval of brepocitinib for dermatomyositis and its supporting VALOR trial data.
Victoria Werth, MD
Advertisement
Victoria Werth, MD, is a professor of Dermatology and Medicine at the University of Pennsylvania and Chief of Dermatology at the Philadelphia VA Medical Center.
Articles by Victoria Werth, MD
LILAC data shows litifilimab rapidly improves CLE skin scores, fueling AMETHYST phase 3 and supporting FDA breakthrough for cutaneous lupus patients.
Victoria Werth, MD, highlights CLE treatment gaps and how BDCA2-targeting litifilimab may quickly curb interferon-driven skin disease with less toxicity.
Advertisement
Latest Updated Articles
From LILAC to AMETHYST: The Rapid Efficacy of Litifilimab in CLEFebruary 12th 2026
Advertisement
Advertisement
Trending on Dermatology Times
1
Body Weight, Not BMI, Associated With Brodalumab Response Trajectory in Plaque Psoriasis
2
FDA Grants QRX003 Rare Pediatric Disease Designation in Peeling Skin Syndrome
3
Former CDC Director Robert Redfield Joins Turn Therapeutics as Chief Scientific Officer
4
Isotretinoin for Adolescent Acne Shows No Cognitive Impairment Despite Rise in Internalizing Symptoms
5